Patent expiry for canakinumab depends on the country and the specific patent family (composition-of-matter, production methods, use indications, etc.). There isn’t a single global expiration date.
Key things to know:
- Patent term: In most jurisdictions, roughly 20 years from the earliest filing date for the patent family, with possible term adjustments or extensions.
- Regulatory data exclusivity: Biologics often have market protection that can outlive patents. For example, the US has 12 years of data exclusivity for new biologics, which can delay generic/biosimilar entry even if the patent expires. The EU has its own data exclusivity framework (typically 8 years data exclusivity + 2 years market exclusivity, with possible extensions for new indications).
- Other protections: Supplementary protection certificates (EU) can extend protection for up to 5 years beyond the base patent term; there can also be pediatric or other regulatory extensions in some regions.
Because there are multiple patent families (antibody composition, manufacturing methods, and use indications) and because regional regimes differ, the expiry date varies by jurisdiction.
If you tell me:
- which country/region you care about (e.g., US, EU, UK, Japan, etc.),
- whether you’re asking about the composition-of-matter patent, use patents, or all patents in the family, and
- whether you want to consider regulatory data exclusivity as well,
I can give a more precise, region-specific answer and point you to the relevant patent documents (e.g., US/EP/WO numbers) to verify dates. If you’d like, I can also guide you on how to look this up in Google Patents, the USPTO Patent Center, and the European Patent Register.